Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Chenodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Chenodeoxycholic Acid
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cysteamine Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : AllianceRx Walgreens
Deal Size : Undisclosed
Deal Type : Partnership
Details : As an exclusive partner, AllianceRx Walgreens Prime is able to offer end-to-end solutions for Leadiant Biosciences and Cystaran patients. Cystaran, a topical ophthalmic therapy for the treatment of corneal cystine crystals in patients with cystinosis.
Product Name : Cystaran
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 22, 2022
Lead Product(s) : Cysteamine Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : AllianceRx Walgreens
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : N-Acetyl-D-Mannosamine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Brigham and Women's Hospital | National Human Genome Research Institute | National Institute of Neurological Disorders and Stroke | National Institute of Arthritis and Musculoskeletal and Skin Diseases | NeuroNext
Deal Size : Inapplicable
Deal Type : Inapplicable
Multi-Center Study of ManNAc for GNE Myopathy
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2020
Lead Product(s) : N-Acetyl-D-Mannosamine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Brigham and Women's Hospital | National Human Genome Research Institute | National Institute of Neurological Disorders and Stroke | National Institute of Arthritis and Musculoskeletal and Skin Diseases | NeuroNext
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 131-I Tenatumomab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
November 11, 2015
Lead Product(s) : 131-I Tenatumomab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Medpace, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Recipient : Medical University of Vienna
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 01, 2014
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Recipient : Medical University of Vienna
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 23, 2014
Lead Product(s) : Piperaquine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
November 25, 2013
Lead Product(s) : Piperaquine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : STP206
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
STP206 for the Prevention of Necrotizing Enterocolitis (NEC)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 01, 2013
Lead Product(s) : STP206
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Dana-Farber Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
June 17, 2013
Lead Product(s) : Peg L asparaginase
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Dana-Farber Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
SST0001 (Roneparstat) in Advanced Multiple Myeloma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2013